• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Prime Success Sets the Record Straight Regarding Continued False and Misleading Statements from Sinovac Biotech's Current Board

    6/16/25 7:35:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care
    Get the next $SVA alert in real time by email

    Prime Success L.P., (together with its affiliates, "Prime Success" or "we"), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company") with ownership of approximately 8% of the Company's outstanding shares, today issued a statement in response to the Company's continued false, misleading and outright fabricated claims relating to the upcoming Special Meeting of Shareholders (the "Special Meeting") scheduled for July 8, 2025.

    Prime Success stated:

    "We believe shareholders deserve the truth – which is why we feel compelled to yet again correct the record, this time regarding the "alert" released on June 16 by the Board currently controlling Sinovac (the "1Globe Activist Board"). In addition to considering the below facts, we think our fellow shareholders should ask themselves a simple question: Given their relentless campaign to distort the truth and repeated twisting of reality, why should you believe anything this Board says? The 1Globe Activist Board should stop with the misleading press releases and start issuing dividends to all shareholders.

    Here are the facts:

    1. Our Injunction Does NOT Block Dividends. What the 1Globe Activist Board Claims Is a Lie.

    Our legal filing merely seeks to maintain the status quo and protect the fundamental shareholder rights of Prime Success — rights that the 1Globe Activist Board has gone to extreme lengths to strip from us. The relief we have requested is narrowly tailored and does not seek to stop dividend distribution to any valid shareholder. It puts forward two reasonable requests to maintain the status quo: (1) that our rights as shareholders be protected, and (2) that those rights not be stripped while we wait for the arbitration to be completed.1

    Equiniti, the paying agent, is listed as a respondent only because they would be the executor of a potential court decision. There is no language whatsoever in our petition that asks the court to prevent Equiniti from distributing dividends to other shareholders.

    The 1Globe Activist Board knows this. They read the petition. Yet they chose to lie – again.

    2. There is no "New Lawsuit" – it is a Self-Defense Injunction Request in Response to the 1Globe Activist Board's Ongoing Litigation.

    Let's be absolutely clear: we did not start this legal fight. We are defending ourselves from a Board that has tried — repeatedly — to erase us from the shareholder register.

    Back in March, we formally asked the Company to confirm our shareholder status. They failed to do that. We then followed the terms of the contract and joined an existing arbitration to enforce the rights we paid tens of millions of dollars for 7 years ago, when we invested in Sinovac. Then, on May 6, the 1Globe Activist Board filed a lawsuit in Antigua attempting to cancel our registered shares entirely — stripping us of our voting rights, our dividend rights, and our very identity as shareholders, instead of abiding by the contract and waiting for the arbitrators to issue a ruling. Afterwards, as if that weren't enough, they escalated their assault by filing an emergency interim injunction on May 30, seeking to bar us from exercising our shareholder rights before the July 8 meeting. That's not a defense of governance — that's a coordinated ambush.

    The emergency injunction we filed last week was self-defense, merely asking to preserve the status quo and our ability to exercise our shareholder rights of attending and voting in the shareholder meeting and receiving lawful dividends like everyone else. Nothing more.

    The 1Globe Activist Board left us with no choice but to ask the court not to treat us any differently than the other shareholders, while supporting dividend distribution to all.

    3. The Current Board is Continuing a Pattern of Public Lies.

    • They claim to uphold the Privy Council's ruling — and yet two of the new directors (the self-appointed Chairman Chiang Li and Sven Borho) were not among the five directors validated by the Privy Council. How do imposters become stewards of shareholder trust?
    • They portray the shares we legally acquired through life-saving, capital-risking investment as "invalid." This is a blatant lie and a flagrant attempt to deprive shareholders of their legitimate properties and rights — and an insult to investors who stood by Sinovac when it mattered most.
    • They claim we are blocking the dividend, when in fact we are the ones demanding that it be paid early and fairly.
    • They claim we are trying to double-dip on dividends. That is a lie. Prime Success is a lawful shareholder of both Sinovac Biotech and Sinovac Life Sciences, entities that pay dividends separately from each other. We receive dividends from a company only when all the other shareholders of the company also receive dividends. We are advocating for fair, timely, and pro-rata dividend payments to all shareholders.

    We will not waste further breath cataloging each lie — the resignation of the auditor and the open protest of management have already spoken volumes.

    4. The 1Globe Activist Board Is Weaponizing Dividends — And They Think Shareholders Are Too Blind to Notice.

    The 1Globe Activist Board has turned dividends — your right — into weapons. They deliberately set the record date after the Special Meeting, dangling your $55.00 per share in front of you like a bait: vote for us, or lose your payout, whereas in reality, the dividends have nothing to do with the Special Meeting and should not have anything to do with the Special Meeting.

    This is not governance. This is coercion.

    We call on you to see through the lies, recognize the manipulation, and look to the future.

    We will no longer engage in their game of distractions. We will build, grow, and lead.

    5. The 1Globe Activist Board Has Failed Its Duties.

    The 1Globe Activist Board has:

    • Blatantly lied to your face
    • Deliberately misled the public and shareholders about the nature of our legal action and our intentions
    • Maliciously weaponized the dividend to cling to power
    • Misused Company resources to wage wars against legitimate shareholders of the Company

    They have breached their fiduciary duty. They have misrepresented the truth. And they have done so knowingly, and with impunity.

    These individuals who answer to no one but 1Globe should be held accountable for their actions against you, our fellow shareholders, and the Company.

    Your vote at the Special Meeting will make that happen. SAIF Partners IV L.P., ("SAIF Partners"), has now filed a definitive proxy statement in connection with the special meeting of the shareholders of the Company to be held on Tuesday, July 8, 2025. As we have said before, Sinovac needs a Board that is comprised of professionals focused on building real, lasting value, a Board that will guide the Company forward on a stable, productive path and break the pattern of internal conflict and ongoing litigation fueled by the 1Globe Activist Board.

    We urge all shareholders vote the GOLD proxy card in support of the SAIF nominees and choose the leadership that will best secure our Company's success in the years to come."

    Sincerely,

    Prime Success, L.P.

    About Prime Success, L.P.

    Prime Success is an investment vehicle established by Advantech Capital specifically to invest in Sinovac and Sinovac Life Sciences; Advantech Capital is a private equity fund established in 2016 with a focus on innovation-driven growth opportunities in China.

    1 https://www.law360.com/articles/2353329/investor-seeks-ny-court-s-help-in-sinovac-control-battle

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250616508773/en/

    Media Contact

    Longacre Square Partners

    [email protected]

    Get the next $SVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SVA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SVA
    SEC Filings

    View All

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    7/10/25 9:54:16 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    7/9/25 9:53:38 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    7/9/25 9:55:18 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SINOVAC Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

    Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that on November 12, 2025, it received a delisting determination letter (the "Staff Determination") from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, unless the Company timely requests a hearing before the Nasdaq Hearing Panel, which the Company intends to do, the Company's securities would be subject to suspension and delisting from Nasdaq at the opening of business on November 21, 2025 as a result of the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"

    11/18/25 3:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    /C O R R E C T I O N -- Heng Ren Partners/

    In the news release, Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment, issued Nov. 11, 2025 by Heng Ren Partners over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared b

    11/11/25 5:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment

    BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared by the board. Sinovac's stock has been halted from trading since 2019. As a result, Sinovac shareholders missed out on an extraordinary windfall from the success of its COVID-19 vaccine, CoronaVac, and its billions of dollars in sales during the pandemic due to the trading halt. In July 2025, the current Board paid a $55.00 dividend to shareholders as partial compensation for dividends that h

    11/11/25 5:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Financials

    Live finance-specific insights

    View All

    /C O R R E C T I O N -- Heng Ren Partners/

    In the news release, Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment, issued Nov. 11, 2025 by Heng Ren Partners over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared b

    11/11/25 5:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Newly Elected Directors of Sinovac Hold the First Board Meeting

    Mr. Andrew Y. Yan elected Chairman of the Board New Board Unanimously Resolved to Explore Future Dividend Plans, Conduct Search for New Auditor for Resuming NASDAQ Trading, and Restore Stable Operations of the Company, Amongst Other Things Sinovac Biotech Ltd. (NASDAQ:SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the new Directors), held its first meeting today at the Company's headquar

    7/10/25 7:23:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment

    Special cash dividend is being paid to valid common shareholders who owned SINOVAC as of the close of business on July 7, 2025 Board will continue to prioritize dividend distributions according to its previously announced policy For any questions about the dividend payment process, shareholders should contact Dividend Information Agent D.F. King at [email protected] The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the previously declared US$55.00 per common share special cash dividend is in the process of being paid to valid shareholders who owned SINOVAC shares as of

    7/9/25 12:27:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Leadership Updates

    Live Leadership Updates

    View All

    SINOVAC Announces Appointment of Independent Auditor

    Critical step in improving transparency and resuming trading on NASDAQ The Board of Directors and Management of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Audit Committee of the Board has approved the engagement of UHY LLP ("UHY") headquartered in the U.S. as its independent auditor and registered public accounting firm, effective today, October 24, 2025. UHY is a U.S. member of Urbach Hacker Young International Limited (UHY International), a UK company, and forms part of the international UHY network of legally independent accounting and consulting firms. As a matter of priority, UH

    10/24/25 10:30:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders

    Special Meeting validly adjourned until the appropriate court makes a final decision on validity of the PIPE shares and will be reconvened SAIF and the Dissenting Investor Group's deceptive claims of a "continuation of the Special Meeting" and a pretend "Board" are fake and without legal basis Current Board remains the only valid board of directors of SINOVAC and will continue to govern the Company The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company") today issued the following update to set the record straight regarding the Special Meeting of Shareholders (the "Special Meeting"): The Special Meeting was validly adjourned by SINOVAC Chairman Chian

    7/11/25 4:21:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC

    Court denies Vivo Capital's petition for relief relating to shareholder votes and corporate governance, clearing another legal hurdle for distribution of the US$55.00 per common share special cash dividend Marks fourth unsuccessful legal attempt in deceptive and disparaging campaign by Advantech/Prime or Vivo Capital against current Board and its Chairman New reports from two leading independent proxy advisory firms, Glass Lewis and ISS, firmly recommend shareholders vote to KEEP the current Board chaired by Dr. Chiang Li The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced

    7/7/25 1:46:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

    SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    9/12/24 4:03:46 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

    SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    6/17/24 4:02:44 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Sinovac Biotech, Ltd. (Amendment)

    SC 13G/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    3/20/24 7:33:23 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care